Poor adherence to HIV monitoring and treatment guidelines for HIV-infected injection drug users

HIV Medicine

Volumn 9, Issue 7, 2008, Pages 503-507

  Wood, Evan ^a,b   Kerr, T ^a,b   Zhang, R ^a   Guillemi, S ^a   Palepu, A ^b   Hogg, R S ^a   Montaner, J S G ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antiretroviral therapy; CD4 monitoring; Drug users; HIV treatment initiation; Therapeutic guidelines

Indexed keywords

ANTIRETROVIRUS AGENT; METHADONE;

ADULT; ARTICLE; CANADA; CD4 LYMPHOCYTE COUNT; COCAINE DEPENDENCE; COHORT ANALYSIS; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANADA; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HEROIN DEPENDENCE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; METHADONE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 50149103758     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00582.x     Document Type: Article

References (24)

1. Egger M, May M, Chene G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002; 360: 119-129.
2. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4 cell count is 0.200 to 0.350 × 10(9) cells/L. Ann Intern Med 2003; 139: 810-816.
3. Hammer SM, Squires KE, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337: 725-733.
4. Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society - USA panel. JAMA 2006; 296: 827-843.
5. Bangsberg DR, Acosta EP, Gupta R et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006; 20: 223-231.
6. Wood E, Hogg RS, Harrigan PR, Montaner JS. When to initiate antiretroviral therapy in HIV-1-infected adults: A review for clinicians and patients. Lancet Infect Dis 2005; 5: 407-414.
7. Celentano DD, Galai N, Sethi AK et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001; 15: 1707-1715.
8. Andersen R, Bozzette S, Shapiro M et al. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization Study. Health Serv Res 2000; 35: 389-416.
9. Palepu A, Tyndall MW, Joy R et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: The role of methadone maintenance therapy. Drug Alcohol Depend 2006; 84: 188-194.
10. Vlahov D, Celentano DD. Access to highly active antiretroviral therapy for injection drug users: Adherence, resistance, and death. Cad Saude Publica 2006; 22: 705-718.
11. Bruce RD, Altice FL. Clinical care of the HIV-infected drug user. Infect Dis Clin North Am 2007; 21: 149-179.
12. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA 1998; 280: 544-546.
13. Shapiro MF, Morton SC, McCaffrey DF et al. Variations in the care of HIV-infected adults in the United States: Results from the HIV Cost and Services Utilization Study. JAMA 1999; 281: 2305-2315.
14. Wood E, Montaner JS, Bangsberg D et al. Extending access to HIV antiretroviral therapy to marginalized populations in the developed world. AIDS 2003; 17: 2419-2427.
15. Strathdee SA, Palepu A, Cornelisse PG et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998; 280: 547-549.
16. Liange KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13-22.
17. Spittal PM, Craib KJ, Wood E et al. Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. CMAJ 2002; 166: 894-899.
18. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2003, CD002209.
19. Kerr T, Wodak A, Elliot R, Montaner JS, Wood E. Opioid substitution therapy and HIV/AIDS treatment and prevention. Lancet 2004; 364: 1918-1919.
20. Karon JM, Fleming PL, Steketee RW, De Cock KM. HIV in the United States at the turn of the century: An epidemic in transition. Am J Public Health 2001; 91: 1060-1068.
21. Ostertag S, Wright RE, Broadhead RS, Altice FL. Trust and other characteristics associated with healthcare utilization by injection drug users. J Drug Issues 2006; 6: 953-974.
22. Wood E, Kerr T, Hogg RS, Zhang R, Tyndall MW, Montaner JS. Validity of self-reported antiretroviral therapy use among injection drug users. J Acquir Immune Defic Syndr 2006; 41: 530-531.
23. Tyndall MW, Currie S, Spittal P et al. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS 2003; 17: 887-893.
24. Strathdee SA, Galai N, Safaeian M et al. Sex differences in risk factors for HIV seroconversion among injection drug users: A 10-year perspective. Arch Intern Med 2001; 161: 1281-1288.